Details
Acylated GLP-1 analog with a half-life of 160 h. Semaglutide is under evaluation for the management of diabetes II. Due to its prolonged half-life, the peptide has to be injected only once per week.
Bachem provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (\"Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Bachem against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.
Item Number4091661SynonymsNN9535Molecular FormulaC₁₈₇H₂₉₁N₄₅O₅₉Relative Molecular Mass4113.64CAS Registry Number[910463-68-2] netSourceSyntheticStorage Conditions-20 ± 5 °CAreas of Interest Diabetes Links / Documents:
Brochures:
Product citations
J.Lau et al., J. Med. Chem., 58, 7370 (2015) C.F.Gotfredsen et al., Diabetes, 63, 2486 (2014)
